Taking the starch out of hereditary colorectal cancer
- PMID: 23140760
- PMCID: PMC3793258
- DOI: 10.1016/S1470-2045(12)70501-6
Taking the starch out of hereditary colorectal cancer
Conflict of interest statement
I declare that I have no conflicts of interest.
Comment on
-
Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.Lancet Oncol. 2012 Dec;13(12):1242-9. doi: 10.1016/S1470-2045(12)70475-8. Epub 2012 Nov 7. Lancet Oncol. 2012. PMID: 23140761 Clinical Trial.
References
-
- Mathers JC, Movahedi M, Macrae F, et al. on behalf of the CAPP2 Investigators. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncol. 2012 published online Nov 7. http://dx.doi.org/10.1016/S1470-2045(12)70475-8. - DOI - PubMed
-
- Boland CR. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer. 2005;4:211–18. - PubMed
-
- Burn J, Bishop DT, Mecklin JP, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008;359:2567–78. - PubMed
-
- Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10:501–07. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
